Abstract
The title compound [systematic name: 1-[(1R,2R,3S,4R)-2,3-dihydroxy-4-methyltetrahydrofuranyl]-5-fluoropyrimidine-2,4(1H,3H)-dione], C9H11FN2O5, is a prodrug of 5-fluorouracil used as a cytostatic in cancer therapy. Its crystal structure was determined from laboratory X-ray powder diffraction data. The compound crystallises in the triclinic space group P1 with two molecules in the asymmetric unit. These symmetrically independent molecules differ in their hydrogen-bond patterns, the pseudorotational angles P of their furanosyl fragments as well as their N-glycosidic torsion angles χ. The crystal structure of 5′-deoxy-5-fluorouridine, 1-[(1R,2R,3S,4R)-2,3-dihydroxy-4-methyltetrahydrofuranyl]-5-fluoropyrimidine-2,4(1H,3H)-dione], C9H11FN2O5, a prodrug of 5-fluorouracil used as a cytostatic in cancer therapy, was determined from laboratory X-ray powder diffraction data. The compound crystallises in the triclinic space group P1 with two symmetrically independent molecules differing in their hydrogen-bond patterns, the pseudorotational angles P of their furanosyl fragments as well as their N-glycosidic torsion angles χ.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
